在HNF1A-MODY (MODY3) -a随机,双盲,安慰剂控制,交叉试验中的empagliflozin

Henrik Maagensen¹, Stine O Høyerup¹, Johanne S Jensen¹

¹Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.

Diabetes care

|January 12, 2026

概括

恩帕格利弗洛辛可显著改善HNF1A-MODY患者的葡萄糖水平,HNF1A-MODY是一种单一性糖尿病,而不会增加低血糖的风险. 这项研究表明,SGLT2抑制剂可以作为这种疾病的有效补充治疗方法.

科学领域:

内分泌学在内分泌学.
遗传学遗传学是一个
药理学药理学是指药理学的学科.

背景情况:

由于HNF1A变异的年轻人成熟期糖尿病 (MODY) 是常见的,通常需要强化治疗,超出一线硫基尿素.
HNF1A影响SGLT2,使得SGLT2抑制剂在HNF1A-MODY中的有效性不确定.

研究的目的:

评估SGLT2抑制剂empagliflozin在HNF1A-MODY患者中作为附加治疗的降糖效应.

主要方法:

一个随机,双盲,安慰剂控制的交叉试验 (MOD3ST-TRIAL) 涉及HNF1A-MODY.患者的成年人.
参与者接受了empagliflozin (25毫克) 治疗4周,其次是安慰剂,或者反之亦然,两周的洗期.
主要结局是10天持续血糖监测 (CGM) 的平均葡萄糖度.

主要成果:

与安慰剂相比,empagliflozin显著降低了平均葡萄糖水平2.3 mmol/L (P = 0.0001).与安慰剂相比,empagliflozin显著降低了平均葡萄糖水平2.3 mmol/L (P = 0.0001).
在empagliflozin和安慰剂之间没有观察到低血糖症的显著差异.
副作用是轻微的和短暂的,没有与empagliflozin相关的严重事件或中止.

结论:

恩帕格利弗洛辛与其他降血糖药物一起使用4周,在HNF1A-MODY患者中显著改善了血糖.
治疗并没有显著增加低血糖或不良反应的风险.

相关概念视频

01:23

Dipeptidyl Peptidase 4 Inhibitors

575

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

575

01:06

Oral Hypoglycemic Agents: Glinides

593

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

593

01:22

Diabetes Mellitus: Type 2 and Gestational

4.3K

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

4.3K

01:24

Glucagon-like Receptor Agonists

836

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

836

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

521

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

521

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

581

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

581